Howard Capital Management Inc. Grows Holdings in Thermo Fisher Scientific Inc. $TMO

Howard Capital Management Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 29.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,979 shares of the medical research company’s stock after buying an additional 670 shares during the period. Howard Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $1,209,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter worth about $532,360,000. EdgePoint Investment Group Inc. bought a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. Auto Owners Insurance Co lifted its stake in Thermo Fisher Scientific by 6,773.5% during the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock worth $143,309,000 after purchasing an additional 283,810 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Thermo Fisher Scientific by 18.3% during the first quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock worth $878,795,000 after purchasing an additional 272,747 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 7,250 shares of the business’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,420 shares of company stock worth $28,134,684 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on TMO shares. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. HSBC reissued a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Citigroup raised their price target on Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a report on Wednesday, October 8th. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $594.65.

Thermo Fisher Scientific Stock Performance

TMO opened at $558.18 on Wednesday. The business’s 50 day moving average is $506.77 and its 200-day moving average is $455.26. The stock has a market cap of $210.77 billion, a PE ratio of 32.25, a price-to-earnings-growth ratio of 3.30 and a beta of 0.77. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.